US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer

Narayan, P; Dilawari, A; Osgood, C; Feng, Z; Bloomquist, E; Pierce, WF; Jafri, S; Kalavar, S; Kondratovich, M; Jha, P; Ghosh, S; Tang, SH; Pazdur, R; Beaver, JA; Amiri-Kordestani, L

Narayan, P (通讯作者)，US FDA, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA.

JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (11): 2108

Abstract

PURPOSEThe US Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (DS-8201a, T-DXd) for the treatment of adult patients with unresec......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索